According to Zacks, “LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. “
Several other equities analysts have also commented on the stock. Lake Street Capital increased their target price on shares of LeMaitre Vascular to $27.00 and gave the company a hold rating in a report on Wednesday, February 20th. BidaskClub raised shares of LeMaitre Vascular from a hold rating to a buy rating in a report on Friday, March 1st. ValuEngine lowered shares of LeMaitre Vascular from a hold rating to a sell rating in a report on Monday, January 7th. Finally, Roth Capital reaffirmed a neutral rating on shares of LeMaitre Vascular in a report on Thursday, February 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $33.29.
LMAT stock opened at $28.63 on Friday. LeMaitre Vascular has a 52 week low of $21.79 and a 52 week high of $41.28. The firm has a market cap of $572.01 million, a P/E ratio of 34.08, a price-to-earnings-growth ratio of 2.97 and a beta of 1.15.
LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, February 19th. The medical instruments supplier reported $0.24 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.24. LeMaitre Vascular had a net margin of 21.73% and a return on equity of 17.71%. The company had revenue of $28.39 million for the quarter, compared to analyst estimates of $26.06 million. On average, research analysts forecast that LeMaitre Vascular will post 0.84 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, April 5th. Investors of record on Friday, March 22nd were issued a dividend of $0.085 per share. The ex-dividend date was Thursday, March 21st. This represents a $0.34 annualized dividend and a dividend yield of 1.19%. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.07. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 40.48%.
In other LeMaitre Vascular news, insider Trent G. Kamke sold 16,604 shares of the firm’s stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $29.63, for a total value of $491,976.52. Following the sale, the insider now owns 19,857 shares of the company’s stock, valued at approximately $588,362.91. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 20.30% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Bank of Montreal Can grew its holdings in LeMaitre Vascular by 99.1% in the 4th quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 554 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in LeMaitre Vascular by 151.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,513 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 912 shares during the last quarter. Quantamental Technologies LLC bought a new stake in LeMaitre Vascular in the 4th quarter worth $49,000. Municipal Employees Retirement System of Michigan bought a new stake in LeMaitre Vascular in the 4th quarter worth $106,000. Finally, First Trust Advisors LP bought a new stake in LeMaitre Vascular in the 3rd quarter worth $214,000. 76.52% of the stock is currently owned by institutional investors and hedge funds.
About LeMaitre Vascular
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More: What is a Candlestick Chart?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.